AbbVie (ABBV) Is Considered a Good Investment by Brokers: Is That True?

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

22.10.2026

AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination

22.10.2026

AbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidradenitis Suppurativa

In the Phase 3 INTREPID study, lutikizumab achieved the primary endpoint of Hidradenitis Suppurativa Clinical Response 75 (HiSCR75) at Week 16 compared with placebo1 Lutikizumab met 8 ranked secondary endpoints, including significant improvements in HS-related skin pain at Week 8 and significant reductions in the occurrence of HS flares over the first 16 weeks,1 reflecting outcomes assessed by both patients and physicians Lutikizumab was generally well tolerated, with no new safety concerns identified1 INTREPID provides Phase 3 data supporting the continued investigation of simultaneous inhibition of IL-1α and IL-1β as a potential treatment approach in adults and adolescents with moderate to severe HS1 NORTH CHICAGO, Ill., Oct. 22, 2026 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from the Phase 3 INTREPID study evaluating the safety and efficacy of lutikizumab, an investigational dual-variable-domain interleukin (IL) 1α/1β antagonist, in adults and adolescents with moderate to severe hidradenitis suppurativa (HS).

22.10.2026

These 3 Dividend Stocks Paid Out Over 90% of Free Cash Flow, but 1 Has Raised Its Dividend 54 Years in a Row

Three popular dividend stocks are paying out well above their free cash flow, and the gap between what each one earns and what it sends to shareholders reveals very different risks hiding behind familiar, trusted names.

21.10.2026

AbbVie (ABBV) Stock Declines While Market Improves: Some Information for Investors

The latest trading day saw AbbVie (ABBV) settling at $284.8, representing a -1.48% change from its previous close.

21.10.2026

AbbVie vs. Bristol Myers Squibb: Faster Growth or Steady Revenue?

AbbVie currently looks stronger on revenue by consistently generating higher overall totals and demonstrating a faster growth trajectory across the measured periods. Both companies record quarter-over-quarter declines at the start of the year, but they maintain generally upward trajectories over the last eight quarters, with AbbVie showing wider increases.

21.10.2026

Forget Social Security: 5 High-Yield Stocks Retirees Are Buying Instead

Social Security raises are locked to a government formula, but a growing number of retirees are routing their income strategy around it entirely, and the stocks they are buying span five very different industries.

Videolar

24.08.2026

Positive

Emily Field: Large pharma companies are going to continue looking at biotech

14.08.2026

Positive

Expert explains why healthcare is a top-performing sector

Reytinglar oshishi / pasayishi

Ticker	Tashkilot	Reyting o‘zgarishi	Maqsadli narx	Sana
ABBV	Wolfe Research	Outperform	undefined >> $300	August 13th 2026
ABBV	Erste Group	Buy	undefined >> undefined	August 5th 2026

Press-relizlar

22.10.2026

AbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidradenitis Suppurativa

AbbVie Inc. (ABBV)

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Biz bilan bog'lanish

Bizni kuzating

AbbVie Inc. (ABBV)

AbbVie (ABBV) Is Considered a Good Investment by Brokers: Is That True?

AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination

AbbVie Announces Topline Results from the Phase 3 INTREPID Trial Showing Lutikizumab Significantly Improved Signs and Symptoms of Disease in Patients with Hidradenitis Suppurativa

These 3 Dividend Stocks Paid Out Over 90% of Free Cash Flow, but 1 Has Raised Its Dividend 54 Years in a Row

AbbVie (ABBV) Stock Declines While Market Improves: Some Information for Investors

AbbVie vs. Bristol Myers Squibb: Faster Growth or Steady Revenue?